Guardant Health (GH) Stock Forecast, Price Target & Predictions
GH Stock Forecast
Guardant Health stock forecast is as follows: an average price target of $68.86 (represents a 178.45% upside from GH’s last price of $24.73) and a rating consensus of 'Buy', based on 10 wall street analysts offering a 1-year stock forecast.
GH Price Target
The average price target for Guardant Health (GH) is $68.86 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $125.00 to $28.00. This represents a potential 178.45% upside from GH's last price of $24.73.
GH Analyst Ratings
According to 10 Wall Street analysts, Guardant Health's rating consensus is 'Buy'. The analyst rating breakdown for GH stock is 0 'Strong Buy' (0.00%), 10 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Guardant Health Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 24, 2024 | Chase Knickerbocker | Craig-Hallum | $28.00 | $17.93 | 56.12% | 13.22% |
| Sep 27, 2023 | David Westenberg | Piper Sandler | $40.00 | $27.59 | 44.98% | 61.75% |
| Feb 06, 2023 | - | Goldman Sachs | $45.00 | $29.56 | 52.23% | 81.97% |
| Dec 16, 2022 | Tejas Savant | Morgan Stanley | $80.00 | $41.26 | 93.89% | 223.49% |
| Dec 16, 2022 | Kyle Mikson | Canaccord Genuity | $65.00 | $41.26 | 57.54% | 162.84% |
| Oct 05, 2022 | Mason Carrico | Stephens | $99.00 | $59.78 | 65.61% | 300.32% |
| Aug 08, 2022 | - | Goldman Sachs | $80.00 | $54.25 | 47.47% | 223.49% |
| May 09, 2022 | Julia Qin | J.P. Morgan | $125.00 | $39.32 | 217.90% | 405.46% |
| Jun 03, 2021 | Matthew Sykes | Goldman Sachs | $160.00 | $117.90 | 35.71% | 546.99% |
The latest Guardant Health stock forecast, released on Apr 24, 2024 by Chase Knickerbocker from Craig-Hallum, set a price target of $28.00, which represents a 56.12% increase from the stock price at the time of the forecast ($17.93), and a 13.22% increase from GH last price ($24.73).
Guardant Health Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 2 |
| Avg Price Target | $28.00 | $28.00 | $34.00 |
| Last Closing Price | $24.73 | $24.73 | $24.73 |
| Upside/Downside | 13.22% | 13.22% | 37.48% |
In the current month, the average price target of Guardant Health stock is $28.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 13.22% increase as opposed to Guardant Health's last price of $24.73. This month's average price target is down 0.00% compared to last quarter, and down -17.65% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Feb 23, 2024 | William Blair | Outperform | Outperform | Hold |
| Nov 13, 2023 | Raymond James | - | Outperform | Upgrade |
| May 26, 2023 | Piper Sandler | - | Overweight | Initialise |
| Feb 06, 2023 | Goldman Sachs | Buy | Buy | Hold |
| Jan 05, 2023 | Scotiabank | - | Sector Outperform | Initialise |
| Oct 06, 2022 | Stephens | - | Overweight | Initialise |
| Aug 08, 2022 | Goldman Sachs | Buy | Buy | Hold |
| May 09, 2022 | J.P. Morgan | Buy | Buy | Hold |
| Feb 24, 2022 | Wells Fargo | Overweight | Overweight | Hold |
| Feb 24, 2022 | Morgan Stanley | Overweight | Overweight | Hold |
Guardant Health's last stock rating was published by William Blair on Feb 23, 2024. The company gave GH a "Outperform" rating, the same as its previous rate.
Guardant Health Financial Forecast
Guardant Health Revenue Forecast
| Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $128.71M | $126.89M | - | - | $96.10M | $108.11M | $94.78M | $92.10M | $78.67M | $78.32M | $74.57M | $66.33M | $67.51M | $62.90M | $60.85M |
| Avg Forecast | $265.24M | $248.94M | $237.08M | $226.81M | $219.76M | $205.29M | $196.57M | $188.68M | $181.97M | $168.98M | $162.25M | $150.09M | $149.60M | $137.35M | $129.85M | $117.87M | $123.82M | $117.75M | $105.08M | $95.77M | $98.65M | $92.01M | $84.52M | $73.75M | $76.74M | $65.93M | $59.18M | $56.48M | $54.87M | $45.41M |
| High Forecast | $270.33M | $253.72M | $241.63M | $231.16M | $223.98M | $209.24M | $200.34M | $192.30M | $185.46M | $172.14M | $164.99M | $154.51M | $152.47M | $143.08M | $132.34M | $120.14M | $126.20M | $120.01M | $107.10M | $100.36M | $103.38M | $96.42M | $88.57M | $77.28M | $80.42M | $69.09M | $62.02M | $59.19M | $57.51M | $47.59M |
| Low Forecast | $258.70M | $242.81M | $231.24M | $221.22M | $214.35M | $200.24M | $191.73M | $184.03M | $177.49M | $164.41M | $159.64M | $146.25M | $145.91M | $130.28M | $126.65M | $114.97M | $120.77M | $114.85M | $102.49M | $92.61M | $95.40M | $88.98M | $81.73M | $71.32M | $74.21M | $63.76M | $57.23M | $54.62M | $53.07M | $43.92M |
| # Analysts | 3 | 4 | 5 | 6 | 5 | 2 | 2 | 2 | 3 | 7 | 13 | 13 | 10 | 16 | 8 | 10 | 13 | 7 | 7 | 9 | 14 | 8 | 8 | 11 | 12 | 16 | 9 | 9 | 8 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.09% | 1.02% | - | - | 1.00% | 1.10% | 1.03% | 1.09% | 1.07% | 1.02% | 1.13% | 1.12% | 1.20% | 1.15% | 1.34% |
Guardant Health's average Quarter revenue forecast for Jul 23 based on 8 analysts is $129.85M, with a low forecast of $126.65M, and a high forecast of $132.34M. GH's average Quarter revenue forecast represents a 0.88% increase compared to the company's last Quarter revenue of $128.71M (Mar 23).
Guardant Health EBITDA Forecast
| Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 4 | 5 | 6 | 5 | 2 | 2 | 2 | 3 | 7 | 13 | 13 | 10 | 16 | 8 | 10 | 13 | 7 | 7 | 9 | 14 | 8 | 8 | 11 | 12 | 16 | 9 | 9 | 8 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-132.65M | $-138.69M | - | - | $-115.41M | $-84.17M | $-101.24M | $-91.22M | $-103.89M | $-84.14M | $-76.63M | $-48.90M | $-22.90M | $-19.73M | $-9.76M |
| Avg Forecast | $-216.55M | $-203.24M | $-193.56M | $-185.17M | $-179.42M | $-167.61M | $-160.48M | $-154.04M | $-148.56M | $-137.96M | $-132.47M | $-139.64M | $-124.87M | $-100.72M | $-171.32M | $-126.95M | $-113.52M | $-91.57M | $-155.75M | $-115.41M | $-103.20M | $-83.24M | $-81.78M | $-80.55M | $-71.39M | $-75.79M | $-26.89M | $-28.78M | $-22.28M | $-14.24M |
| High Forecast | $-211.21M | $-198.24M | $-188.79M | $-180.61M | $-175.00M | $-163.48M | $-156.53M | $-150.25M | $-144.91M | $-134.23M | $-130.34M | $-111.71M | $-99.89M | $-80.58M | $-137.06M | $-101.56M | $-90.81M | $-73.25M | $-124.60M | $-92.33M | $-82.56M | $-66.59M | $-65.43M | $-64.44M | $-57.12M | $-60.63M | $-21.52M | $-23.02M | $-17.82M | $-11.40M |
| Low Forecast | $-220.71M | $-207.15M | $-197.28M | $-188.73M | $-182.87M | $-170.83M | $-163.57M | $-157.00M | $-151.42M | $-140.54M | $-134.70M | $-167.57M | $-149.84M | $-120.87M | $-205.58M | $-152.34M | $-136.22M | $-109.88M | $-186.89M | $-138.49M | $-123.84M | $-99.89M | $-98.14M | $-96.65M | $-85.67M | $-90.95M | $-32.27M | $-34.53M | $-26.73M | $-17.09M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.04% | 1.22% | - | - | 1.00% | 0.82% | 1.22% | 1.12% | 1.29% | 1.18% | 1.01% | 1.82% | 0.80% | 0.89% | 0.69% |
undefined analysts predict GH's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Guardant Health's previous annual EBITDA (undefined) of $NaN.
Guardant Health Net Income Forecast
| Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 4 | 5 | 6 | 5 | 2 | 2 | 2 | 3 | 7 | 13 | 13 | 10 | 16 | 8 | 10 | 13 | 7 | 7 | 9 | 14 | 8 | 8 | 11 | 12 | 16 | 9 | 9 | 8 | 9 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-133.53M | $-139.93M | - | - | $-123.23M | $-72.31M | $-107.53M | $-97.58M | $-109.66M | $-93.75M | $-77.67M | $-54.64M | $-27.73M | $-25.21M | $-12.79M |
| Avg Forecast | $-65.82M | $-73.35M | $-82.03M | $-80.92M | $-80.86M | $-87.19M | $-90.53M | $-91.07M | $-88.61M | $-91.91M | $-94.05M | $-149.11M | $-134.87M | $-106.98M | $-182.18M | $-135.55M | $-122.61M | $-97.25M | $-165.62M | $-123.23M | $-111.46M | $-88.41M | $-87.48M | $-85.02M | $-79.54M | $-76.82M | $-30.05M | $-34.84M | $-28.46M | $-18.67M |
| High Forecast | $-63.71M | $-71.00M | $-79.40M | $-78.33M | $-78.27M | $-84.40M | $-87.63M | $-88.15M | $-85.77M | $-82.17M | $-87.23M | $-119.28M | $-107.90M | $-85.58M | $-145.74M | $-108.44M | $-98.09M | $-77.80M | $-132.49M | $-98.58M | $-89.17M | $-70.73M | $-69.98M | $-68.01M | $-63.63M | $-61.46M | $-24.04M | $-27.87M | $-22.77M | $-14.93M |
| Low Forecast | $-67.46M | $-75.18M | $-84.08M | $-82.94M | $-82.88M | $-89.37M | $-92.79M | $-93.34M | $-90.82M | $-100.27M | $-99.50M | $-178.93M | $-161.85M | $-128.37M | $-218.62M | $-162.66M | $-147.13M | $-116.70M | $-198.74M | $-147.87M | $-133.76M | $-106.09M | $-104.98M | $-102.02M | $-95.45M | $-92.19M | $-36.06M | $-41.81M | $-34.16M | $-22.40M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.99% | 1.14% | - | - | 1.00% | 0.65% | 1.22% | 1.12% | 1.29% | 1.18% | 1.01% | 1.82% | 0.80% | 0.89% | 0.69% |
Guardant Health's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. GH's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Guardant Health SG&A Forecast
| Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 4 | 5 | 6 | 5 | 2 | 2 | 2 | 3 | 7 | 13 | 13 | 10 | 16 | 8 | 10 | 13 | 7 | 7 | 9 | 14 | 8 | 8 | 11 | 12 | 16 | 9 | 9 | 8 | 9 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $116.57M | $119.31M | - | - | $105.70M | $99.87M | $100.28M | $96.09M | $102.27M | $100.79M | $91.39M | $62.20M | $44.90M | $41.15M | $35.24M |
| Avg Forecast | $243.57M | $228.60M | $217.71M | $208.28M | $201.81M | $188.52M | $180.51M | $173.26M | $167.10M | $155.18M | $148.99M | $127.90M | $148.17M | $99.77M | $93.13M | $116.27M | $113.70M | $90.70M | $84.66M | $87.94M | $90.59M | $82.45M | $77.61M | $67.72M | $70.47M | $60.54M | $34.21M | $56.41M | $46.46M | $41.70M |
| High Forecast | $248.24M | $232.99M | $221.89M | $212.28M | $205.68M | $192.14M | $183.97M | $176.59M | $170.31M | $158.08M | $151.51M | $153.47M | $177.80M | $119.72M | $111.75M | $139.52M | $115.89M | $108.84M | $101.59M | $92.16M | $94.93M | $98.95M | $81.33M | $70.97M | $73.84M | $63.44M | $41.05M | $67.70M | $55.75M | $43.70M |
| Low Forecast | $237.57M | $222.97M | $212.35M | $203.15M | $196.84M | $183.88M | $176.06M | $168.99M | $162.99M | $150.97M | $146.60M | $102.32M | $118.53M | $79.82M | $74.50M | $93.02M | $110.90M | $72.56M | $67.73M | $85.05M | $87.61M | $65.96M | $75.06M | $65.49M | $68.15M | $58.55M | $27.37M | $45.13M | $37.16M | $40.33M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00% | 1.05% | - | - | 1.20% | 1.10% | 1.22% | 1.24% | 1.51% | 1.43% | 1.51% | 1.82% | 0.80% | 0.89% | 0.85% |
Guardant Health's average Quarter SG&A projection for Jul 23 is $93.13M, based on 8 Wall Street analysts, with a range of $74.50M to $111.75M. The forecast indicates a -20.11% fall compared to GH last annual SG&A of $116.57M (Mar 23).
Guardant Health EPS Forecast
| Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 4 | 5 | 6 | 5 | 2 | 2 | 2 | 3 | 7 | 13 | 13 | 10 | 16 | 8 | 10 | 13 | 7 | 7 | 9 | 14 | 8 | 8 | 11 | 12 | 16 | 9 | 9 | 8 | 9 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-1.30 | $-1.36 | - | - | $-1.21 | $-0.71 | $-1.06 | $-0.96 | $-1.09 | $-0.94 | $-0.78 | $-0.57 | $-0.29 | $-0.27 | $-0.14 |
| Avg Forecast | $-0.54 | $-0.60 | $-0.67 | $-0.66 | $-0.66 | $-0.72 | $-0.74 | $-0.75 | $-0.73 | $-0.76 | $-0.77 | $-0.87 | $-0.86 | $-0.97 | $-1.22 | $-1.34 | $-1.40 | $-1.28 | $-1.21 | $-1.21 | $-1.11 | $-0.88 | $-0.82 | $-0.89 | $-0.57 | $-0.39 | $-0.37 | $-0.39 | $-0.30 | $-0.38 |
| High Forecast | $-0.52 | $-0.58 | $-0.65 | $-0.64 | $-0.64 | $-0.69 | $-0.72 | $-0.72 | $-0.70 | $-0.68 | $-0.72 | $-0.81 | $-0.77 | $-0.72 | $-1.18 | $-1.29 | $-1.36 | $-1.24 | $-1.18 | $-1.16 | $-1.06 | $-0.85 | $-0.78 | $-0.85 | $-0.54 | $-0.37 | $-0.35 | $-0.38 | $-0.29 | $-0.36 |
| Low Forecast | $-0.55 | $-0.62 | $-0.69 | $-0.68 | $-0.68 | $-0.73 | $-0.76 | $-0.77 | $-0.75 | $-0.82 | $-0.82 | $-0.96 | $-0.94 | $-1.11 | $-1.25 | $-1.37 | $-1.44 | $-1.31 | $-1.24 | $-1.29 | $-1.18 | $-0.94 | $-0.87 | $-0.94 | $-0.60 | $-0.41 | $-0.39 | $-0.42 | $-0.32 | $-0.40 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.97% | 0.97% | - | - | 1.00% | 0.64% | 1.20% | 1.17% | 1.23% | 1.66% | 2.02% | 1.55% | 0.74% | 0.90% | 0.37% |
According to undefined Wall Street analysts, Guardant Health's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to GH previous annual EPS of $NaN (undefined).
Guardant Health Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PSNL | Personalis | $1.52 | $8.50 | 459.21% | Hold |
| ILMN | Illumina | $115.58 | $328.90 | 184.56% | Buy |
| GH | Guardant Health | $24.73 | $68.86 | 178.45% | Buy |
| CSTL | Castle Biosciences | $23.91 | $41.00 | 71.48% | Buy |
| CRL | Charles River Laboratories | $232.82 | $357.67 | 53.63% | Buy |
| CDNA | CareDx | $15.24 | $22.00 | 44.36% | Buy |
| DHR | Danaher | $259.26 | $313.59 | 20.96% | Buy |
| TMO | Thermo Fisher Scientific | $594.80 | $640.00 | 7.60% | Buy |
| A | Agilent | $151.28 | $151.29 | 0.01% | Buy |
| MYGN | Myriad Genetics | $25.36 | $24.33 | -4.06% | Hold |
| NTRA | Natera | $105.52 | $100.00 | -5.23% | Buy |
| TWST | Twist Bioscience | $48.13 | $38.25 | -20.53% | Buy |
GH Forecast FAQ
Is Guardant Health a good buy?
Yes, according to 10 Wall Street analysts, Guardant Health (GH) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 10 'Buy' recommendations, accounting for 100.00% of GH's total ratings.
What is GH's price target?
Guardant Health (GH) average price target is $68.86 with a range of $28 to $125, implying a 178.45% from its last price of $24.73. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Guardant Health stock go up soon?
According to Wall Street analysts' prediction for GH stock, the company can go up by 178.45% (from the last price of $24.73 to the average price target of $68.86), up by 405.46% based on the highest stock price target, and up by 13.22% based on the lowest stock price target.
Can Guardant Health stock reach $40?
GH's average twelve months analyst stock price target of $68.86 supports the claim that Guardant Health can reach $40 in the near future.
What is Guardant Health's current price target trend?
1 Wall Street analyst forecast a $28 price target for Guardant Health (GH) this month, up 13.22% from its last price of $24.73. Compared to the last 3 and 12 months, the average price target increased by 13.22% and increased by 37.48%, respectively.
What are Guardant Health's analysts' financial forecasts?
Guardant Health's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $810.3M (high $825.86M, low $790.34M), average EBITDA is $-662M (high $-645M, low $-674M), average net income is $-350M (high $-338M, low $-358M), average SG&A $744.09M (high $758.39M, low $725.77M), and average EPS is $-2.873 (high $-2.781, low $-2.944). GH's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $978.07M (high $996.86M, low $953.98M), average EBITDA is $-799M (high $-779M, low $-814M), average net income is $-302M (high $-292M, low $-310M), average SG&A $898.15M (high $915.41M, low $876.03M), and average EPS is $-2.482 (high $-2.403, low $-2.544).
Did the GH's actual financial results beat the analysts' financial forecasts?
Based on Guardant Health's last annual report (Dec 2022), the company's revenue was $449.54M, beating the average analysts forecast of $442.41M by 1.61%. Apple's EBITDA was $-651M, beating the average prediction of $-476M by 36.67%. The company's net income was $-655M, beating the average estimation of $-509M by 28.68%. Apple's SG&A was $463.78M, beating the average forecast of $377M by 23.02%. Lastly, the company's EPS was $-6.41, beating the average prediction of $-5.109 by 25.46%. In terms of the last quarterly report (Mar 2023), Guardant Health's revenue was $128.71M, beating the average analysts' forecast of $117.87M by 9.20%. The company's EBITDA was $-133M, beating the average prediction of $-127M by 4.49%. Guardant Health's net income was $-134M, missing the average estimation of $-136M by -1.49%. The company's SG&A was $116.57M, beating the average forecast of $116.27M by 0.26%. Lastly, the company's EPS was $-1.3, missing the average prediction of $-1.338 by -2.82%